Antiproliferative effect of bitter melon (momordica charantia) seed and fruit extracts through the non-genomic oestrogen receptor signaling pathway on oestrogen-sensitive endometrium cancer cells

Abstract

Background and Aims: Momordica charantia has garnered much attention as an alternative medicine due to its phytopharmaceutical content and anti-cancer properties. This study aimed to demonstrate the anti-cancer potential of M. charantia fruit extract (McFE) and seed extract (McSE) by investigating their effects on the migration and proliferation of human endometrial cancer (EC) cells as well as on the activation (phosphorylation) of non-genomic oestrogen receptor (ER) signaling pathway kinases and caspase-9 phosphorylation. Methods: McFE and McSE samples were extracted with ethanol using the maceration method. The MTT (3-[4,5-dimethylthiazol-2-yl]−2,5 diphenyl tetrazolium bromide) test was used to evaluate EC cell (RL 95-2) viability, Western blot was used to analyse protein phosphorylation, and cell migration was evaluated using a wound-healing assay. Results: Cell proliferation was inhibited by McSE and McFE, with IC₅₀ values of 134,8 μg/mL and 165,9 μg/ mL, respectively. The phosphorylation of non-genomic ER signaling kinases, such as extracellular signalregulated kinases (ERK1/2) (8.59-fold), P38 mitogen-activated protein kinase (P38MAPK) (13.99-fold), and protein kinase B (AKT) (4.52-fold), increased in comparison to control cells after a short (15 min.) treatment with low concentrations (1 nM) of 17 β-oestradiol. The phosphorylation of caspase-9 (Thr125 2.59 fold, Ser196 3.48 fold) was additionally elevated by oestradiol treatment. The activation of ERK1/2, P38MAPK and AKT, and the phosphorylation of caspase-9 were significantly decreased by treatment with McSE and McFE. Additionally, the relative closure of the scratch in the cell migration assay was significantly reduced after treatment with McSE and McFE. Conclusion: M. charantia can induce cell death in EC cells by preventing the phosphorylation of caspase-9 and non-genomic kinases involved in the ER signaling pathway. These findings imply that M. charantia could be used as an alternative supportive treatment for EC.

Keywords

• 17 β-oestradiol
• Endometrium cancer
• Non-genomic oestrogen signaling pathway
• Caspase-9
• Momordica charantia

References

1. Allan, L. A., Morrice, N., Brady, S., Magee, G., Pathak, S., & Clarke, P. R. (2003). Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nature Cell Biology, 5, 647-654. https://doi.org/10.1038/ncb1005 google scholar
2. Allen, N. E., Tsilidis, K. K., Key, T. J., Dossus, L., Kaaks, R., Lund, E., Bakken, K., Gavrilyuk, O., Overvad, K., Tjpnneland, A., Olsen, A., Fournier, A., Fabre, A., Clavel-Chapelon, F., Chabbert-Buffet, N., Sacerdote, C., Krogh, V., Bendinelli, B., Tumino, R., . . . Riboli, E. (2010). Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. American journal of epidemiology, 172, 1394-1403. https://doi.org/10.1093/aje/kwq300 google scholar
3. Arnal, J. F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B., & Katzenellenbogen, J. (2017). Membrane and nuclear estrogen receptor alpha actions: from tissue speci-ficity to medical implications. Physiological reviews, 97, 1045-1087. https://doi. org/10.1152/physrev.00024.2016 google scholar
4. A sta, C., Pasayeva, L., Imamoglu, N., & Cumaoglu, A. (2023). Momordica charantia in-hibits prostate cancer cell proliferation by suppressing dihydrotestosterone-induced caspase-9 phosphorylation. Iranian Journal of Science, 47, 1487-1496. https://doi.org/10.1007/s40995-023-01546-z google scholar
5. Basaran, G.S., Bekci, H., Baldemir, A., Ilgun, S., & Cumaoglu, A. (2020). Momordica charantia seed and aryl extracts potentiate growth inhibition and apoptosis by dual blocking of PI3K/AKT and MAPK pathways as a downstream target of EGFR signaling in breast cancer cells. Current Nutrition & Food Science, 16, 726-733. https://doi.org/10.2174/1573401315666190712214922 google scholar
6. Bokhman J. V. (1983). Two pathogenetic types of endometrial carcinoma. Gynecologic oncology, 15, 10-17. https://doi.org/10.1016/0090-8258(83)90111-7 google scholar
7. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science, 282, 1318-1321. https://doi.org/10.1126/science.282. 5392.1318 google scholar
8. Carlson, M. J., Thiel, K. W., & Leslie, K. K. (2014). Past, present, and future of hormonal therapy in recurrent endometrial cancer. International Journal of Women's Health, 6, 429-435. https://doi.org/10.2147/IJWH.S40942 google scholar

9. Chao, C. Y., Sung, P. J., Wang, W. H., & Kuo, Y. H. (2014). Anti-inflammatory effect of Momordica charantia in sepsis mice. Molecules, 19, 12777-12788. https://doi. org/10.3390/molecules190812777 google scholar
10. Çınar, H., & Cumaoğlu, A., (2023). Momordica charantia seed extract inhibits breast cancer cell proliferation and migration by suppressing the activation of non-genomic estrogen receptor signaling kinases and caspase-9 phosphory-lation. Current Topıcs in Phytochemıstry, 19, 25-33. google scholar
11. Dos Santos, E. G., Dieudonne, M. N., Pecquery, R., Le Moal, V., Giudicelli, Y., & Lacasa, D. (2002). Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinol-ogy, 143, 930-940. https://doi.org/10.1210/endo.143.3.8678 google scholar
12. Erdogan, K., & Eroglu, O. (2022). The extract of Momordica charantia inhibits cell proliferation and migration in U87G cells. Biology Bulletin, 49, 31-38. https:// doi.org/10.1134/S1062359022130040 google scholar
13. Fang, E. F., Zhang, C. Z. Y., Wong, J. H., Shen, J. Y., Li, C. H., & Ng, T. B. (2012). The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Letters, 324, 66-74. https://doi. org/10.1016/j.canlet.2012.05.005 google scholar
14. Feldman, R. D., & Limbird, L. E. (2017). GPER (GPR30): A nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and can-cer. Annual Review of Pharmacology and Toxicology, 57, 567-584. https://doi. org/10.1146/annurev-pharmtox-010716-104651 google scholar
15. Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Advances in Protein Chemistry and Structural Biology, 116, 135-170. https://doi.org/10. 1016/bs.apcsb.2019.01.001 google scholar
16. Grada, A., Otero-Vinas, M., Prieto-Castrillo, F., Obagi, Z., & Falanga, V. (2017). Research techniques made simple: analysis of collective cell migration using the wound healing assay. The Journal of Investigative Dermatology, 137, e11-e16. https:// doi.org/10.1016/j.jid.2016.11.020 google scholar
17. Grover, J. K., & Yadav, S. P. (2004). Pharmacological actions and potential uses of Momordica charantia: a review. Journal of Ethnopharmacology, 93, 123-132. https://doi.org/10.1016/j.jep.2004.03.035 google scholar
18. Gu, H. Z., Lin, R. R., Wang, H. C., Zhu, X. J., Hu, Y., & Zheng, F. Y. (2017). Effect of Momordica charantia protein on proliferation, apoptosis and the AKT signal transduction pathway in the human endometrial carcinoma Ishikawa H cell line in vitro. Oncology Letters, 13, 3032-3038. https://doi.org/10.3892/ol.2017. 5830 google scholar
19. Gu, Q., & Moss, R. L. (1996). 17 beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 16, 3620-3629. https://doi.org/10.1523/ JNEUROSCI.16-11-03620.1996 google scholar
20. He, Y. Y., Du, G. Q., Cai, B., Yan, Q., Zhou, L., Chen, X. Y., Lu, W., Yang, Y. X., & Wan, X. P. (2012). Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2. Journal of Cancer Research and Clinical Oncology, 138, 775-783. https://doi.org/10.1007/s00432-011-1133-7 google scholar
21. Hsu, H. Y., Lin, J. H., Li, C. J., Tsang, S. F., Tsai, C. H., Chyuan, J. H., Chiu, S. J., & Chuang, S. E. (2012). Antimigratory effects of the methanol extract from Momordica charan-tia on human lung adenocarcinoma CL1 Cells. Evidence-Based Complementary and Alternative Medicine, 2012, 819632. https://doi.org/10.1155/2012/819632 google scholar
22. Jia, M., Dahlman-Wright, K., & Gustafsson, J. A. (2015). Estrogen receptor alpha and beta in health and disease. Best Practice & Research. Clinical Endocrinology & Metabolism, 29, 557-568. https://doi.org/10.1016/j.beem.2015.04.008 google scholar
23. Johnson, G. L., & Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298, 1911-1912. https:// doi.org/10.1126/science.1072682 google scholar
24. Joseph, B., & Jini, D. (2013). Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pacific Journal of Tropical Disease, 3, 93-102. https://doi.org/10.1016/S2222-1808(13)60052-3 google scholar
25. Kaaks, R., Lukanova, A., & Kurzer, M. S. (2002). Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 11, 1531-1543. google scholar
26. Lortet-Tieulent, J., Ferlay, J., Bray, F., & Jemal, A. (2018). International patterns and trends in endometrial cancer incidence, 1978-2013. Journal of the National Cancer Institute, 110, 354-361. https://doi.org/10.1093/jnci/djx214 google scholar
27. Lösel, R., & Wehling, M. (2003). Nongenomic actions of steroid hormones. Nature Reviews. Molecular Cell Biology, 4, 46-56. https://doi.org/10.1038/nrm1009 google scholar
28. Marino, M., & Ascenzi, P. (2008). Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell prolifera-tion. Steroids, 73, 853-858. https://doi.Org/10.1016/J.steroids.2007.12.003 google scholar
29. Marino, M., Acconcia, F., & Trentalance, A. (2003). Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Molec-ular Biology of the Cell, 14, 2583-2591. https://doi.org/10.1091/mbc.e02-09-0621 google scholar
30. Marino, M., Pallottini, V., & Trentalance, A. (1998). Estrogens cause rapid activation of IP3-PKC-alpha signal transduction pathway in HEPG2 cells. Biochemical and Biophysical Research Communications, 245, 254-258. https://doi.org/10.1006/ bbrc.1998.8413 google scholar
31. Ranasinghe, K. N. K., Premarathna, A. D., Mahakapuge, T. A. N., WiJesundera, K. K., Ambagaspitiya, A. T., Jayasooriya, A. P., Kularatne, S. A. M., & RaJapakse, R. P. V. J. (2021). In vivo anticancer effects of Momordica charantia seed fat on hepatocellular carcinoma in a rat model. Journal of Ayurveda and Integrative Medicine, 12, 435-442. https://doi.org/10.1016/J.Jaim.2021.03.001 google scholar
32. Salehi, B., Zucca, P., Sharifi-Rad, M., Pezzani, R., RaJabi, S., Setzer, W. N., Varoni, E. M., Iriti, M., Kobarfard, F., & Sharifi-Rad, J. (2018). Phytotherapeutics in cancer invasion and metastasis. Phytotherapy Research, 32, 1425-1449. https://doi.org/10.1002/ ptr.6087 google scholar
33. Seval, Y., Cakmak, H., Kayisli, U. A., & Arici, A. (2006). Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium. The Journal of Clinical Endocrinology and Metabolism, 91, 2349-2357. https://doi.org/10.1210/ Jc.2005-2132 google scholar
34. Shen, F., Gao, Y., Ding, J., & Chen, Q. (2017). Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?. Oncotarget, 8, 506-511. https://doi.org/10.18632/oncotarget.13471 google scholar
35. Shi, X., Wang, J., Lei, Y., Cong, C., Tan, D., & Zhou, X. (2019). Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review). Molecular Medicine Reports, 19, 4529-4535. https://doi.org/10.3892/mmr.2019.10121 google scholar
36. Shi, Y. (2002). Mechanisms of caspase activation and inhibition during apopto-sis. Molecular cell, 9, 459-470. https://doi.org/10.1016/s1097-2765(02)00482-3 google scholar
37. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., SoerJomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 google scholar
38. van Meerloo, J., Kaspers, G. J., & Cloos, J. (2011). Cell sensitivity assays: the MTT assay. Methods in Molecular Biology, 731, 237-245. https://doi.org/10.1007/978-1-61779-080-5_20 google scholar
39. Venkatraman, D., Ravichandran, S., Kabilan, N., & Dev, D. (2021). In vitro anticancer activity of ethanolic extract of pericarp and seed parts of Momordica charantia on colon cancer cell lines. Journal of Pharmacognosy and Phytochemistry, 10, 224-229. https://doi.org/10.22271/phyto.2021.v10.i3c.14078 google scholar
40. Vrtacnik, P., Ostanek, B., MenceJ-Bedrac, S., & Marc, J. (2014). The many faces of estrogen signaling. Biochemia Medica, 24, 329-342. https://doi.org/10.11613/ BM.2014.035 google scholar
41. Yang, S., Thiel, K. W., & Leslie, K. K. (2011). Progesterone: the ultimate endometrial tumor suppressor. Trends in Endocrinology and Metabolism, 22, 145-152. https://doi.org/10.1016/J.tem.2011.01.005 google scholar
42. Yung, M. M., Ross, F. A., Hardie, D. G., Leung, T. H., Zhan, J., Ngan, H. Y., & Chan, D. W. (2016). Bitter melon (Momordica charantia) extract inhibits tumorigenicity and overcomes cisplatin-resistance in ovarian cancer cells through targeting AMPK signaling cascade. Integrative Cancer Therapies, 15, 376-389. https://doi. org/10.1177/1534735415611747 google scholar